ImmunityBio

ImmunityBio is a vertically-integrated biotechnology company founded in 2014, focused on developing next-generation immunotherapies and vaccines designed to enhance the natural immune system for combating cancers and infectious diseases. The company's core strategy involves leveraging its immunotherapy and cell therapy platforms to generate sustained immune responses, aiming for durable and safe disease protection. A key product, ANKTIVA, is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer with CIS, which activates natural killer cells, T cells, and memory T cells for prolonged efficacy. ImmunityBio is also developing potential cancer vaccines and other immunotherapies and cell therapies intended to be more effective, accessible, and easily administered than current oncology and infectious disease standards of care.

Operating with an employee range of 500 - 1,000 individuals across 4 locations, ImmunityBio is committed to advancing its pipeline. The company's scientific approach aims to sharply reduce or eliminate the need for high-dose chemotherapy by applying its platforms to treat various cancers and infectious diseases. This includes developing off-the-shelf cell therapies and biological molecules. For insights into the people driving these innovations, you can Meet ImmunityBio's team. The company's ticker symbol is NASDAQ: IBRX.

With a reported revenue of $141.0M, ImmunityBio has secured significant funding rounds, including substantial debt and equity financing, to support its research and development efforts. Its product candidates are designed for both treatment and prevention, targeting diseases like HIV and various cancers. The company's competitive landscape includes numerous biotechnology and pharmaceutical firms. Investors and stakeholders can Explore financial highlights for detailed metrics andView more...